You are Trying to View a Premium Article

Daily News You Can't Find Anywhere Else

Novartis Snaps Up Xiidra Eye Drops in $5.3 Billion Deal


Industry Segment: Pharmaceutical & Biotech | Word Count: 635 Words
Attachment: Novartis

GALWAY, IRELAND--May 27, 2019--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Swiss pharmaceutical company Novartis International AG (NYSE:NVS) (Basel, Switzerland) has agreed a $5.3 billion deal to purchase a number of eye-disease medicines from Takeda Pharmaceutical (Osaka, Japan).

Within this article: Details $5.3 billion deal, impact of drug, current sales, direction of Novartis and Takeda, related sales

This Premium Article can be purchased individually or as part of a subscription

Subscribe Now! All Fields Required...

Subscription Type: Pricing Help?

  • Pay-Per-Article - $3.95
  • Annual Subscription - $235.00
  • Annual Subscription with Archive - $395.00